Allurion Announces New U.S. Patents for Next-Gen Weight Loss Device
Allurion Technologies, Inc. (NYSE: ALUR), a company focused on ending obesity, announced today that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) for its next-generation weight loss device. These patents are scheduled to be issued on March 11, 2025. The patents include U.S. Patent No. 12,246,163 titled “Automatic-Sealing Balloon-Filling Catheter System” and U.S. Patent No. 12,245,962 titled “Balloon Sealing and Fill Valve.” These patents expand on the company’s proprietary Balloon technology for treating obesity, featuring enhanced balloon filling mechanisms and innovative systems for controlling balloon opening. The patents will provide protection for the company through April 2043. With these two new patents, Allurion now holds 22 patents in the U.S. and 64 patents globally.
The Allurion Program is a comprehensive weight-loss platform that integrates the Allurion Gastric Balloon, the first and only swallowable, procedure-less™ gastric balloon designed for weight loss, with the Allurion Virtual Care Suite. The suite includes the Allurion Mobile App and Connected Scale for consumers, and Allurion Insights for healthcare providers, powered by the Iris AI Platform. The program enables patients to lose 10-15% of their total body weight, with certain studies also showing an increase in muscle mass.
Shantanu Gaur, Founder and CEO of Allurion, expressed excitement about the new patents and their role in enhancing the Allurion Balloon’s design. “With the issuance of these two patents, we now have 22 issued patents in the U.S. and 64 issued patents globally,” said Gaur. “As we begin new clinical trials to combine the Allurion Balloon with GLP-1 therapy, we aim to continuously improve our product’s design and manufacturing processes, with the goal of setting a new gold standard in obesity treatment.”
The Allurion Gastric Balloon is part of the Allurion Program, which is designed to help individuals achieve sustainable weight loss without the need for surgery or invasive procedures. The balloon is placed into the stomach through swallowing, making it a unique and non-invasive option compared to traditional weight-loss procedures that often require surgery. Once inside the stomach, the balloon takes up space, helping individuals feel fuller faster, leading to reduced food intake.
Beyond the gastric balloon, the Allurion Program offers a comprehensive virtual care suite that integrates digital tools to track and support weight loss. The Allurion Mobile App and Connected Scale allow patients to track their progress, while the Allurion Insights platform provides healthcare providers with key data to personalize and monitor patient care.
This suite is designed to improve the overall patient experience, guiding them throughout their weight-loss journey with continuous monitoring and support. Allurion’s Iris AI Platform within the Insights platform further enhances patient care by offering data-driven insights and recommendations to healthcare providers.
Allurion’s commitment to advancing its technology is evident in its ongoing research and development efforts. The company is exploring new clinical trials aimed at combining the Allurion Balloon with GLP-1 therapy, a class of drugs that have shown promise in the management of obesity. This combination is expected to enhance the effectiveness of weight loss and potentially offer new solutions for patients struggling with obesity. As Allurion moves forward with its clinical trials, the company is determined to enhance its product offerings and solidify its position as a leader in the obesity treatment space.
In addition to expanding its patent portfolio, Allurion continues to focus on increasing access to its weight-loss platform. The company is committed to providing a non-surgical, cost-effective solution for individuals battling obesity. With the global obesity epidemic affecting millions, Allurion’s innovative approach offers a viable alternative to traditional surgical weight-loss options, potentially improving outcomes for those who struggle with obesity and related health conditions.
About Allurion
Allurion is a company dedicated to ending obesity. The Allurion Program combines the Allurion Gastric Balloon, the first and only swallowable, procedure-less™ gastric balloon for weight loss, with the Allurion Virtual Care Suite. The suite includes the Allurion Mobile App for consumers, Allurion Insights for healthcare providers, and the Allurion Connected Scale. Allurion’s focus on creating accessible, effective, and non-invasive weight-loss solutions has made it a leader in the field. The Allurion Gastric Balloon is currently an investigational device in the United States.
